Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds.
| Revenue (TTM) | 49,890 |
| Gross Profit (TTM) | -645 |
| EBITDA | $-4.79M |
| Operating Margin | -10568.00% |
| Return on Equity | -1569.00% |
| Return on Assets | -58.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.18 |
| Price-to-Book | 1.37 |
| Price-to-Sales (TTM) | 112.29 |
| EV/Revenue | 85.56 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 267.40% |
| Shares Outstanding | $7.37M |
| Float | $2.53M |
| % Insiders | 0.00% |
| % Institutions | 0.66% |